SCHEMBL3570002

SCHEMBL3570002

Cc1ccc(NC=C2C(=O)Nc3cc(C(=O)c4cccc(C(N)=O)c4)ccc32)cc1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT2 P31751 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDPK1 O15530 1/20 0.38
MAP3K7 O43318 2/20 0.38
TAB1 Q15750 2/20 0.38
AURKB Q96GD4 3/20 0.37
KIT P10721 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
FLT3 P36888 1/20 0.36
RAB9A P51151 1/20 0.36
RAF1 P04049 1/20 0.36
NTRK1 P04629 1/20 0.35
TGM2 P21980 1/20 0.35
CDYL2 Q8N8U2 1/20 0.35
CDYL Q9Y232 1/20 0.35
CDY1; CDY1B Q9Y6F8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3578279 0.94 TGM2 (0.37) LMNAMAPTHTTSMN1; SMN2PDPK1
SCHEMBL4757664 0.93 PDPK1 (0.46) AKT2LMNAMAPTHTTSMN1; SMN2
SCHEMBL3572328 0.93 PDPK1 (0.46) AKT2LMNAMAPTHTTSMN1; SMN2
SCHEMBL3570007 0.92 LMNA (0.45) LMNAMAPTHTTSMN1; SMN2PDPK1
SCHEMBL3578283 0.89 PIM1 (0.42) LMNAMAPTHTTSMN1; SMN2MAP3K7
SCHEMBL3579462 0.89 NTRK3 (0.47) AKT2LMNAMAPTHTTSMN1; SMN2
SCHEMBL3579464 0.89 NTRK3 (0.47) AKT2LMNAMAPTHTTSMN1; SMN2
SCHEMBL3572683 0.89 FLT3 (0.43) AKT2AURKBFLT4KDRFLT3
SCHEMBL3581636 0.87 PDPK1 (0.43) AKT2PDPK1RAF1NTRK1TGM2
SCHEMBL3575692 0.87 MAP3K7 (0.47) AKT2MAPTSMN1; SMN2PDPK1MAP3K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 AKT2 94/4885LMNA 4717/4885MAPT 1650/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 AKT2 168/4885LMNA 4604/4885MAPT 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.